PropertyValue
?:abstract
  • Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo While ivermectin\'s activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns
is ?:annotates of
?:creator
?:journal
  • Journal_of_Controlled_Release
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Ivermectin: An award-winning drug with antiviral expectations against COVID-19
?:type
?:who_covidence_id
  • #837981
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/tdvahhqm>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/tdvahhqm>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all